Blood Plasma Derivatives Market Size

Market Size Snapshot

Note – Market size depicts the revenue generated over the financial year

The value of the blood plasma derivatives market is estimated to be $46.9 billion in 2023, and is expected to reach $96.9 billion by 2032, at a CAGR of 9.41% from 2024 to 2032. The rapid growth of the market is attributed to the development of medical technology and the rising prevalence of chronic diseases that require treatment. As the medical system develops, the focus on individual medicine and the development of new therapies is driving the market. The key growth drivers are the increasing use of blood derivatives such as albumin, globulin and thrombin in the treatment of various conditions such as hemophilia, immune deficiency and liver diseases. The advancement in the collection and processing of blood products and the strategic initiatives of leading companies will enhance the availability and effectiveness of these products. Several leading companies, such as Grifols, CSL Behring and Takeda, are expanding their product portfolio and strengthening their global presence through strategic alliances and acquisitions. These strategic moves not only strengthen their position in the market, but also ensure the availability of high-quality blood derivatives to meet the growing demand.

Regional Market Size

Regional Deep Dive

The Blood Plasma Derivatives Market is characterized by high growth potential in all regions, owing to the rising demand for products derived from human blood plasma. The North American region is characterized by the advanced health care system, the high prevalence of chronic diseases and the strong focus on research and development. Europe has a strong regulatory framework that encourages innovation and ensures product safety. The Asia-Pacific region is characterized by rapid advancements in manufacturing capabilities and rising health care expenditures. The Middle East and Africa region is characterized by a challenging regulatory framework and varying health care systems, but also by opportunities for growth as the public becomes more aware of the benefits of blood-derived therapies. Latin America is gradually becoming more important, owing to the strengthening health care system and the increasing investment in biotechnology.

Europe

• The European Medicines Agency (EMA) has introduced new regulations aimed at accelerating the approval process for innovative plasma-derived therapies, fostering a more dynamic market environment.
• Companies such as Octapharma and Takeda are actively collaborating with research institutions to develop next-generation therapies, which is expected to enhance treatment options for patients with rare diseases.

Asia Pacific

• China has recently implemented policies to promote the collection of blood plasma, leading to a significant increase in domestic plasma supply and a burgeoning market for derivatives.
• Innovations in manufacturing technologies, such as the use of artificial intelligence in plasma fractionation processes, are being adopted by companies like Shandong Taibang Biological Products, enhancing efficiency and product quality.

Latin America

• Brazil has seen a rise in public-private partnerships aimed at enhancing plasma collection and processing capabilities, which is expected to boost the local market for plasma derivatives.
• Regulatory bodies in countries like Argentina are working to harmonize standards for plasma-derived products, which could facilitate trade and improve access to these therapies across the region.

North America

• The U.S. Food and Drug Administration (FDA) has recently updated guidelines for the collection and use of blood plasma, which is expected to streamline processes and enhance the safety of plasma-derived products.
• Key players like Grifols and CSL Behring are investing heavily in expanding their production facilities in North America, which is anticipated to increase the availability of critical plasma-derived therapies.

Middle East And Africa

• The World Health Organization (WHO) has launched initiatives to improve blood donation rates in Africa, which is crucial for increasing the availability of plasma for therapeutic use.
• Local companies are beginning to emerge, such as Biovac, which is focusing on developing plasma-derived products tailored to regional health needs, potentially transforming the market landscape.

Did You Know?

“Did you know that approximately 55% of human blood is plasma, and it contains vital proteins that are essential for blood clotting and immune system functions?” — American Red Cross

Segmental Market Size

The blood derivatives market is a crucial part of the biopharmaceutical industry and is currently experiencing stable growth, driven by the increasing demand for IgG and coagulation factor concentrates. In addition to the growing number of people suffering from chronic illnesses such as haemophilia and immune deficiencies, the development of new and more efficient methods of blood collection are driving the market. Regulations, especially in North America and Europe, are also creating a favourable environment for the development of blood-derived products, by ensuring that they meet the required quality and safety standards. The market is currently in a stage of maturity, with Grifols and CSL Behring leading the way in the production and distribution of blood-derived products. In particular, IgG is vital in the treatment of autoimmune disorders and in surgery, where it is used as an essential component of infusion therapy. Lastly, the growing interest in convalescent plasma therapies and the pandemic of COVID-09 have encouraged the development of convalescent plasma therapies. Lastly, the need for companies to reduce their carbon footprint is encouraging them to explore more efficient methods of blood collection. The development of new technology, such as the use of pathogen reduction systems, is shaping the evolution of the market and ensuring the safety and efficacy of blood-derived products.

Future Outlook

As the result of these experiments, it was found that the growth of the market for blood and its products from $46.9 billion in 2023 to $95 billion in 2032 was due to the increasing number of products on the market. " The main reason for this was the increased use of blood derivatives in all therapeutic areas. In the most developed countries, where the health system is well developed, it is possible that the use of blood derivatives will reach up to 30 percent by 2032. And the main reason for this is the development of new products and new techniques for obtaining blood and its products. In the future, the efficiency and safety of blood derivatives will be further improved by the development of recombinant therapies and new fractionation methods. In addition, favorable regulatory conditions and increased investments in R & D will stimulate innovation in this field. Also, the development of new trends, such as the increasing acceptance of individualized medicine and the development of blood donation programs, will further increase the growth of the market. As the world population grows and the demand for effective treatment increases, the blood and its products market will continue to develop, bringing new opportunities for investors to the end of the decade.